Acrivon reports Q2 2026 results, flags ACR-368 interim data for second half of 2026
Acrivon says its Phase 2b interim analysis in serous endometrial cancer is on track for the second half of 2026 as ACR-2316 moves into randomized dose expansion.
SEC filing